Other languages Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.77 ^USD	-3.80%		-1.12%	+15.69%

May. 14	Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
May. 14	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell	May. 14
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction	May. 14
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire	Apr. 29
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024	Apr. 29
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024	Apr. 29
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients	Mar. 12
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	Mar. 12
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump	Mar. 11
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell	Mar. 11
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08
Lexicon Enrolls First Patient in Phase 2b Trial of Potential Non-Opioid Drug for Diabetic Neuropathic Pain	Nov. 30
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain	Nov. 30
Lexicon Pharmaceuticals, Inc. Announces Post Hoc Analysis of Clinical Data from the SCORED Trial	Nov. 12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Other languages

Filters